North America, Europe, and Asia-Pacific Large Molecule Bioanalysis Testing Services Market Research Report Forecast to 2030
북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장은 첨단 기술 및 신뢰할 수 있는 고분자 바이오 분석 테스트 서비스에 대한 수요 증가, 임상시험 서비스 아웃소싱 추세 증가, 임상시험 증가 등으로 인해 성장하고 있습니다. 그러나 적절한 분석 기술 개발의 어려움은 시장 성장을 억제하고 있습니다. 또한, 만성 질환의 유행은 시장에 유리한 성장 기회를 제공할 것으로 예상됩니다.
지역별 분석
북미가 2022년 45.29%로 가장 큰 시장 점유율을 차지할 것으로 예상되며, 시장 규모는 2030년까지 약 14억 9,885만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 8.70% 성장할 것으로 예상됩니다. 그러나 아시아태평양이 2030년까지 11.52%의 가장 높은 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.
이 보고서는 북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장을 조사 분석했으며, 시장 역학, 지역 및 부문 분석, 기업 프로파일 등의 정보를 제공합니다.
목차
제1장 주요 요약
제2장 시장 서론
제3장 조사 방법
제4장 시장 역학
제5장 시장 요인 분석
- 밸류체인 분석
- 고객 획득(구입 전 문의)
- 서비스 커스터마이즈
- 고객 구입 지원
- 고객 풀필먼트 및 구입 후 지원
- Porter의 Five Forces 분석 모델
- 북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장에 대한 COVID-19의 영향
- 공급망에 대한 영향
- 서비스 제공업체에 대한 영향
제6장 북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장 : 시험 유형별
- 개요
- 약물 동태(PK) 연구
- 약력학(PD) 연구
- 생물학적 동등성 연구
- 바이오마커 시험
- 면역원성 시험
- 기타
제7장 북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장 : 치료 영역별
- 개요
- 종양
- 감염증
- 순환기 질환
- 신경
- 자가면역 질환
- 기타
제8장 북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장 : 최종사용자별
- 개요
- 제약 기업 및 바이오의약품 기업
- 수탁 개발 제조 조직(CDMO)
- 임상시험 수탁기관(CRO)
- 학술연구기관
- 기타
제9장 북미, 유럽, 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장 : 지역별
- 개요
- 북미
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 스위스
- 네덜란드
- 벨기에
- 스웨덴
- 노르웨이
- 덴마크
- 아일랜드
- 핀란드
- 기타 유럽
- 아시아태평양
제10장 경쟁 구도
- 개요
- 경쟁 벤치마킹
- 고분자 바이오 어널리시스 주요 기업 : 카테고리별
- 고분자 생물 분석 주요 기업 : 제약 기업별
- 고분자 생물 분석 주요 기업 : CDMO별
- 고분자 생물 분석 주요 기업 : CRO별
- 고분자 생물 분석 주요 기업 : 학술연구기관 별
- 북미, 유럽, 아시아태평양 고분자 바이오 분석 테스트 서비스 시장의 주요 성장 전략
- 북미, 유럽, 아시아태평양 고분자 바이오 분석 테스트 서비스 시장의 개발 건수 기준 주요 기업
- 주요 개발 분석
- 주요 발전과 성장 전략
- 주요 기업의 재무 상황
제11장 기업 개요
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- PPD INC
- EUROFINS SCIENTIFIC
- WUXI APPTEC
- QPS HOLDINGS
- BIO-TECHNE
- ICON PLC
- CHARLES RIVER LABORATORIES
- SGS SOCIETE GENERALE DE SURVEILLANCE SA
- BIOAGILYTIX LABS
- SMITHERS
- MESO SCALE DIAGNOSTICS, LLC
- CMIC HOLDINGS CO., LTD
제12장 참고 자료
LSH
Market Overview
The market for large molecule bioanalysis testing services in North America, Europe, and Asia-Pacific is expanding due to rising demand for high-tech and dependable large molecule bioanalytical testing services, a growing trend of outsourcing laboratory testing services, and an increase in the number of clinical trials. However, the difficulties in developing appropriate analytical techniques are limiting the growth of the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market. Furthermore, the growing prevalence of chronic diseases is expected to provide lucrative growth opportunities for the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market.
The concentration of large molecules in biological samples such as proteins and antibodies are determined using large molecule bioanalytical testing services. Large molecules are frequently utilized in drug development, and bioanalytical testing is required to ensure these drugs' safety and efficacy.
The expected growth in market can be attributed to the increasing demand for high-tech and reliable large molecule bioanalytical testing services, growing trend of outsourcing laboratory testing services, and rising R&D expenditure in the biopharmaceutical sector. However, the market is also held back by challenges in the development of proper analytical techniques. Nevertheless, it is anticipated that the growing incidence of chronic diseases will create lucrative opportunities for the players operating in the North America, Europe, And Asia-Pacific large molecule bioanalysis testing services market.
MARKET SEGMENTATION
Based on test type, the large molecule bioanalysis testing market has been segmented into pharmacokinetic (PK) studies, pharmacodynamic studies, bioequivalence studies, immunogenicity testing, biomarker testing and others.
Based on therapeutic area, the market has been segmented into oncology, infectious diseases, cardiovascular diseases, neurology, autoimmune disorders, and others.
Based on test type, the market has been segmented into pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), academic and research institutes, and others.
Regional Analysis
Based on region, the large molecule bioanalysis testing services market has been segmented into North America, Europe, and Asia-Pacific. North America accounted for the largest market share of 45.29% in 2022 and is anticipated to reach approximately USD 1,498.85 million by 2030 at an 8.70% CAGR during the forecast period. However, Asia-Pacific is projected to register the highest CAGR of 11.52% by 2030.
MAJOR PLAYERS
America Holdings (US), ICON plc (Ireland), SGS Societe Generale de Surveillance SA (Switzerland), WuXi AppTec (China), Charles River Laboratories (US), Eurofins Scientific (luxembourg), QPS Holdings (US), BioTechne (US), PPD, Inc (US), BioAgilytix Labs (US), Smithers (US), Meso Scale Diagnostic, LLC (US), and CMIC HOLDINGS CO., LTD (Japan).
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING DEMAND FOR HIGH-TECH AND RELIABLE LARGE MOLECULE BIOANALYTICAL TESTING SERVICES
- 4.2.2 GROWING TREND OF OUTSOURCING LABORATORY TESTING SERVICES
- 4.2.3 RISING R&D EXPENDITURE IN THE BIOPHARMACEUTICAL SECTOR
- 4.3 RESTRAINTS
- 4.3.1 CHALLENGES IN THE DEVELOPMENT OF PROPER ANALYTICAL TECHNIQUES
- 4.4 OPPORTUNITIES
- 4.4.1 GROWING INCIDENCE OF CHRONIC DISEASES
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 CUSTOMER ACQUISITION (PRE-PURCHASE QUERY)
- 5.1.2 SERVICE CUSTOMIZATION
- 5.1.3 CUSTOMER PURCHASE SUPPORT
- 5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON SERVICE PROVIDER
6 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE
- 6.1 OVERVIEW
- 6.2 PHARMACOKINETIC (PK) STUDIES
- 6.3 PHARMACODYNAMIC (PD) STUDIES
- 6.4 BIOEQUIVALENCE STUDIES
- 6.5 BIOMARKER TESTING
- 6.6 IMMUNOGENICITY TESTING
- 6.7 OTHERS
7 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY THERAPEUTIC AREA
- 7.1 OVERVIEW
- 7.2 ONCOLOGY
- 7.3 INFECTIOUS DISEASES
- 7.4 CARDIOVASCULAR DISEASE
- 7.5 NEUROLOGY
- 7.6 AUTOIMMUNE DISORDERS
- 7.7 OTHERS
8 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY END USER
- 8.1 OVERVIEW
- 8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
- 8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)
- 8.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
- 8.5 ACADEMIC AND RESEARCH INSTITUTES
- 8.6 OTHERS
9 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY REGION
- 9.1 OVERVIEW
- 9.2 NORTH AMERICA
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 SWITZERLAND
- 9.3.7 NETHERLANDS
- 9.3.8 BELGIUM
- 9.3.9 SWEDEN
- 9.3.10 NORWAY
- 9.3.11 DENMARK
- 9.3.12 IRELAND
- 9.3.13 FINLAND
- 9.3.14 REST OF EUROPE
- 9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
10 COMPETITIVE LANDSCAPE
- 10.1 OVERVIEW
- 10.2 COMPETITIVE BENCHMARKING
- 10.3 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CATEGORY
- 10.3.1 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY PHARMA
- 10.3.2 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CDMO
- 10.3.3 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CRO
- 10.3.4 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY ACADEMIC AND RESEARCH INSTITUTIONS
- 10.4 MAJOR GROWTH STRATEGY IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET
- 10.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET
- 10.6 KEY DEVELOPMENT ANALYSIS
- 10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.8 MAJOR PLAYERS FINANCIAL
- 10.8.1 SALES (USD MILLION), 2022
- 10.8.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022
11 COMPANY PROFILES
- 11.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 SERVICES OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
- 11.2 PPD INC
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 SERVICES OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
- 11.3 EUROFINS SCIENTIFIC
- 11.3.1 COMPANY OVERVIEWS
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 SERVICES OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
- 11.4 WUXI APPTEC
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 SERVICES OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
- 11.5 QPS HOLDINGS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 SERVICES OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
- 11.6 BIO-TECHNE
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 SERVICES OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
- 11.7 ICON PLC
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 SERVICES OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
- 11.8 CHARLES RIVER LABORATORIES
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 SERVICES OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
- 11.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS/SERVICES OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
- 11.10 BIOAGILYTIX LABS
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 SERVICES OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
- 11.11 SMITHERS
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL ANALYSIS
- 11.11.3 SERVICES OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 KEY STRATEGIES
- 11.12 MESO SCALE DIAGNOSTICS, LLC
- 11.12.1 COMPANY OVERVIEW
- 11.12.2 FINANCIAL ANALYSIS
- 11.12.3 SERVICES OFFERED
- 11.12.4 KEY DEVELOPMENTS
- 11.12.5 KEY STRATEGIES
- 11.13 CMIC HOLDINGS CO., LTD
- 11.13.1 COMPANY OVERVIEW
- 11.13.2 FINANCIAL OVERVIEW
- 11.13.3 SERVICES OFFERED
- 11.13.4 KEY DEVELOPMENTS
- 11.13.5 KEY STRATEGIES
12 REFERENCES
